Skip to main content

Table 2 Individual Demographics, Diagnosis, Treatment, and Outcomes of Osteomyelitis Patients Treated with Ertapenem

From: Ertapenem for treatment of osteomyelitis: a case series

Patient Age (yrs) Race Gender Comorbidities Diagnosis¥ Trauma-related DiagnosticMethod Surgical Intervention No. Days on Erta Other Antibiotic Outcome at One Year£
1 47 White Male None Recurrent chronic contiguous tibial osteomyelitis Yes Bone culture Soft tissue debridement 39 None F-Infection cleared at end of therapy, but recurred by one year
2 56 White Female COPD, DM, Pancreatic cancer Initial chronic hematogenous vertebral osteomyelitis Yes Deep tissue culture None 39 Suppressive moxifloxacin following ertapenem F-Did not clear infection at end of therapy, but cleared by one year
3 70 White Male CAD, PVD Initial chronic contiguous tibial osteomyelitis Yes Bone culture Bone debridement 33 None S-Infection cleared at end of therapy without recurrence at one year
4 41 White Female None Initial acute contiguous toe osteomyelitis Yes MRI None 43 Amoxicillin/clavulanate for 20 days preceding ertapenem S-Infection cleared at end of therapy without recurrence at one year
5 72 White Female PVD, DM, CKD Initial chronic contiguous toe osteomyelitis Not
known
MRI None 41 See footnote1
Suppressive cephalexin following ertapenem
F- Did not clear infection at end of therapy, but cleared by one year
6 64 Black Female PVD, DM Recurrent chronic contiguous malleolar osteomyelitis Not
known
MRI None 35 Vancomycin and ampicillin/sulbactam for 6 days preceding ertapenem; suppressive ciprofloxacinclindamycin following ertapenem F- Did not clear infection at end of therapy, but cleared by one year
7 79 White Female None Initial chronic contiguous calcaneal ostemyelitis No Bone scan None 24 None S-Infection cleared at end of therapy without recurrence at one year
8 76 White Female Neurologic disease Initial acute contiguous calcaneal osteomyelitis No MRI Amputation 26 Imipenem for 14 days following therapy S-Infection cleared at end of therapy without recurrence at one year
9 47 White Female DM Initial chronic contiguous toe osteomyelitis Not
known
MRI None 42 Piperacillin/tazobactam for 9 days prior to ertapenem S-Infection cleared at end of therapy without recurrence at one year
10 37 White Male DM Initial chronic contiguous toe osteomyelitis No MRI None 31 Ampicillin/sulbactam for 3 days prior to ertapenem S-Infection cleared at end of therapy without recurrence at one year
11 48 Black Female PVD, DM Initial acute contiguous toe osteomyelitis No Plain film None 20 Vancomycin for 4 days, piperacillin/tazobactam, 3 days, ceftriaxone for 2 days, all prior to ertapenem F-Did not clear infection at end of therapy, nor by one year
12 86 Black Male CAD, PVD, DM Initial chronic contiguous toe osteomyelitis No MRI None 42 Piperacillin/tazobactam for 5 days prior to ertapenem F- Did not clear infection at end of therapy, but cleared by one year
  1. Comorbidities include chronic obstructive pulmonary disease (COPD), coronary artery disease (CAD), peripheral vascular disease (PVD), diabetes mellitus (DM), cancer, chronic kidney disease (CKD), liver disease, connective tissue disorder, neurologic disease, human immunodeficiency virus (HIV), and hepatitis C virus (HCV).
  2. ¥Classification of osteomyelitis included the following definitions: Acute = less than four weeks of symptoms (bone pain, erythema, tenderness, or exposure through open wound) prior to presentation to a medical provider; chronic = greater than or equal to four weeks of symptoms prior to presentation; initial = first episode of osteomyelitis at current site; recurrent = repeat episode of osteomyelitis at current site; contiguous = any associated wound infection following surgery or trauma or cellulitis at the site of osteomyelitis occurring within two weeks prior to diagnosis; hematogenous = any osteomyelitis without a contiguous focus of infection associated with the osteomyelitis site.
  3. £S = success, defined as resolution of clinical signs and symptoms of infection such that discontinuation of antibiotics was deemed appropriate at end of ertapenem therapy, and no recurrence at one year; F = failure, any case not meeting criteria for success.
  4. 1Vancomycin for five days, ciprofloxacin for one day, metronidazole for two days, ceftazadime for four days, and imipenem for two days, all preceding ertapenem, and six days of clindamycin concurrently with ertapenem.